Sleep experiences during different lifetime periods and in vivo Alzheimer pathologies

Table 1 Demographics and clinical characteristics of study subjects (n = 202)

Age, years	71.07 (6.74)
Female	102 (50.5%)
Education level, years	11.51 (4.77)
APOE4 carrier	37 (18.3%)
Vascular risk score, %	17.49 (15.84)
HDRS	0.74 (1.51)
Current use of any sleep medication	6 (3.0%)
Bad sleep quality (bad + very bad)
Young adulthood	13 (6.4%)
Midlife	21 (10.4%)
Current	24 (11.9%)
Sleep duration, h
Young adulthood	6.83 (1.11)
Midlife	6.65 (1.18)
Current	6.42 (1.31)
Aβ positive	33 (16.3%)
Global Aβ deposition	1.20 (0.25)
AD-ND positive	112 (55.4%)
AD-CM	1.41 (0.12)
AD-CT, mm	2.84 (0.18)

Data are presented as mean (standard deviation) or number (%)
APOE4 apolipoprotein E ε4, HDRS Hamilton Depression Rating Score, Aβ beta-amyloid, AD-ND Alzheimer’s disease signature region neurodegeneration, AD-CM Alzheimer disease signature region cerebral glucose metabolism, AD-CT Alzheimer’s disease signature region cortical thickness

ISSN: 1758-9193